Abbvie-Header Abbvie-Header


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SYT-510

            Therapeutic Area: Psychiatry/Psychology Product Name: SYT-510

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ysios Capital

            Deal Size: $26.6 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing April 20, 2021


            This investment brings total Series A financing to CHF 24 million to complete pre-clinical development and progress lead candidate through proof-of-concept clinical studies. Synendos is advancing the preclinical and clinical development of SYT-510.